Charles Clift is chair of the Medicines Patent Pool, a Swiss charitable foundation seeking to increase access to medicine for people living with HIV in developing countries.
For a large part of his career he worked as an economist in the UK Department for International Development with experience of working in Kenya, India and the Caribbean.
From 2004 to 2006 he was a staff member of the World Health Organization (WHO). In addition to his work for Chatham House, he has been a consultant to the WHO, UNITAID, the World Intellectual Property Organization and the Access to Medicine Foundation.
His research interests at Chatham House include counterfeit medicines, global health governance and financing, and antimicrobial resistance.
He has a BA from The University of Cambridge and an MA and PhD from The University of Sussex.
- Access to medicines in developing countries
- Counterfeit medicines
- Intellectual property, innovation and public health
- Health economics/financing
|2010 -||Independent consultant|
|2007 - 09||Senior Adviser, Access to Medicines, Department for International Development, UK|
|2004 - 06||Secretary, Commission on Intellectual Property Rights, Innovation and Public Health, World Health Organization|
|2001 - 03||Secretary, UK Commission on Intellectual Property Rights|
|Up to 2001||Economic Adviser in UK Department for International Development|
- Towards a New Global Business Model for Antibiotics: Delinking Revenues from Sales Chatham House Report
- What’s the World Health Organization For? Chatham House Report
- The Role of the World Health Organization in the International System Other resource
- Counterfeit Medicines: Health and Harm The World Today
- Counterfeit, Falsified and Substandard Medicines Other resource
- Combating Counterfeit, Falsified and Substandard Medicines: Defining the Way Forward? Chatham House Briefing
- The WHO's New Electoral Format Could Be a Model for Other UN Agencies 07 November 2016
- Is Yet Another Ebola Report a Symptom of the Problem or the Solution? 23 November 2015
- Medicines Pricing: Is There a Better Way? 08 October 2015
- WHO Ebola Report is a Missed Opportunity 14 July 2015
- De-linkage: A Way Forward for Antimicrobial Drugs 13 May 2015
- Devil in the Detail for WHO’s Ebola Resolution 27 January 2015
- Reform of the WHO: Is It on the Right Track? 20 May 2014
- Tackling the Political Origins of Health Inequity 10 February 2014
- Global Health 2035: The 1993 World Development Report Revisited 02 December 2013
- The UK's New Antimicrobial Resistance Strategy 10 September 2013
- Ebola and WHO Reform Global Health Governance, April 2016
- Is Universal Health Coverage Good for Health? Universal Health Coverage and the Post-2015 Development Agenda The World We Want, January 2013
- Why IPR issues were brought to GATT? A historical perspective on the origins of TRIPS in C. Correa (ed.) Research Handbook On The Protection Of Intellectual Property Under WTO Rules, Elgar, 2010
- The value of patent term extensions to the pharmaceutical industry in the USA Journal of Generic Medicines, 2008
- A Guide to Assessing the Impact of TRIPS-Plus Provisions on Drug Prices in Developing Countries International Centre for Trade and Sustainable Development, Geneva, 2007
- Public health, innovation and intellectual property rights: unfinished business with Tomris Türmen, Bulletin of the World Health Organization, Vol.84, 338, 2006